Jones Financial Companies’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Jones Financial Companies’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-216	Closed	-$229	–	4239
2025 Q2	$229	Hold	216	–	–	﹤0.01%	3899
2025 Q1	$257	Buy	+216	New	+$382	﹤0.01%	3571

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Jones Financial Companies's BCLI Position: Q3 2025 in Review

Jones Financial Companies sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 216 shares — an estimated $229 sold.

Jones Financial Companies first reported a position in BCLI in Q1 2025 and held it in 2 quarters. The position peaked at $257 in Q1 2025. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Jones Financial Companies reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Jones Financial Companies sold 216 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $229.
Jones Financial Companies first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2025 and held it in 2 quarters.
Jones Financial Companies's BRAINSTORM CELL THERAPUTC position peaked at $257 in Q1 2025.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Jones Financial Companies's 13F filing for Q3 2025, filed 4 Nov 2025.